Radar Healthcare announces acquisition of Cemplicity
Radar HealthAcquirer
CemplicityTarget
Radar Healthcare announced on August 12, 2026 that it has acquired patient‑experience platform Cemplicity, a deal backed by Marlin Equity Partners with financial terms not disclosed.
Radar Healthcare announced on August 12, 2026 that it has acquired patient‑experience platform Cemplicity, a deal backed by Marlin Equity Partners with financial terms not disclosed.
Deal Terms
The transaction adds Cemplicity’s real‑time patient‑reported outcomes suite to Radar’s existing risk, quality and compliance SaaS platform. Cemplicity, founded in 2013, reported roughly $3 million in annual recurring revenue and serves more than 3,000 facilities across nine countries. Radar, a Leeds‑based provider of enterprise governance, risk and compliance (GRC) software for health and social‑care organizations, has previously expanded its portfolio with the 2025 acquisition of EIDO Healthcare. Both companies will operate under the same private‑equity ownership of Marlin Equity Partners.
Strategic Rationale
The acquisition unifies two historically separate technology stacks: operational governance and patient‑voice analytics. By embedding Cemplicity’s PREMs, PROMs and post‑operative surveillance tools into Radar’s incident‑management and compliance workflows, health systems can trigger risk‑mitigation actions the moment a negative patient signal is recorded. This closed‑loop capability moves organizations from periodic reporting to proactive quality improvement, a shift that aligns with tightening regulatory expectations in the UK, EU and Middle East markets.
Capability Alignment
Radar’s core engine automates incident logging, risk registers and workforce compliance, while Cemplicity supplies real‑time feedback dashboards and longitudinal outcome tracking. The combined platform will enable a single data pipeline that feeds patient‑reported metrics directly into risk‑register updates, corrective‑action plans and audit trails. Early deployments cited in the source show response‑rate improvements of up to 80 % after integrating Cemplicity’s surveys, underscoring the operational upside of the integration.
Geographic Expansion
Cemplicity’s footprint in Australia, New Zealand, South Africa and parts of Europe gives Radar an immediate foothold in the ANZ region, complementing its established presence in the United Kingdom, Europe and the Middle East. The cross‑regional infrastructure is expected to accelerate cross‑selling of Radar’s GRC modules to Cemplicity’s existing customer base and vice‑versa.
Why It Matters
For Radar Healthcare, the deal deepens its value proposition by adding a patient‑experience layer that directly feeds into its risk‑management engine, positioning the company as a one‑stop shop for clinical governance. Competitors that focus solely on compliance, such as Healthicity or Medgate, may now face pressure to broaden their product suites or pursue similar add‑on acquisitions to stay relevant.
Cemplicity gains immediate access to Radar’s extensive NHS and private‑hospital network, which should accelerate its ARR growth beyond the ANZ market. Direct rivals in the patient‑reported outcomes space, like Qualtrics Health or GetWellNetwork, will need to consider how integrated governance capabilities could erode their market share among large health systems seeking consolidated platforms.
Key Points
- Radar Healthcare announced the acquisition of Cemplicity on August 12, 2026.
- The transaction is backed by private‑equity firm Marlin Equity Partners; financial terms were not disclosed.
- Cemplicity brings real‑time PREMs, PROMs and post‑operative surveillance to Radar’s risk and compliance SaaS platform.
- The combined offering creates an end‑to‑end clinical‑governance and patient‑experience ecosystem across the UK, Europe, Middle East, ANZ and South Africa.
- Radar’s previous acquisition of EIDO Healthcare in early 2025 marks the second platform add‑on within an 18‑month window.
Analysis
While the purchase price remains private, the deal reflects a broader trend of health‑tech platforms consolidating to capture higher ARR multiples, typically ranging from 8‑12 × for niche SaaS with strong regulatory lock‑in. By integrating patient‑experience data into a governance framework, Radar can justify premium pricing and improve net revenue retention through cross‑selling. For investors, the transaction underscores Marlin Equity Partners’ buy‑and‑build playbook, where platform companies acquire complementary specialists to expand addressable market and deepen data moats. Operators will likely see increased pressure to adopt unified solutions that combine compliance, risk analytics and patient‑outcome reporting, accelerating the shift toward data‑driven quality improvement in health systems. The move also signals that private‑equity capital will continue to flow into health‑tech SaaS that can demonstrate measurable impact on clinical safety and patient satisfaction, a metric increasingly tied to reimbursement and public‑sector funding.